TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

Ads

You May Also Like

Foresight VCT plc – Half-year report

FORESIGHT VCT PLC Financial Highlights  Total net assets £134.2 million. An interim dividend of ...

Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility

SHANGHAI, China and CUPERTINO, Calif., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group ...

Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation

SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or ...